BR112018071283A2 - célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno. - Google Patents

célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno.

Info

Publication number
BR112018071283A2
BR112018071283A2 BR112018071283A BR112018071283A BR112018071283A2 BR 112018071283 A2 BR112018071283 A2 BR 112018071283A2 BR 112018071283 A BR112018071283 A BR 112018071283A BR 112018071283 A BR112018071283 A BR 112018071283A BR 112018071283 A2 BR112018071283 A2 BR 112018071283A2
Authority
BR
Brazil
Prior art keywords
antigen binding
vectors
cell
binding protein
expressing
Prior art date
Application number
BR112018071283A
Other languages
English (en)
Inventor
Burakov Darya
Chen Gang
P Fandl James
Babb Robert
Zhao Yu
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112018071283A2 publication Critical patent/BR112018071283A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

esta invenção se refere à integração sítio-específica e à expressão de proteínas recombinantes em células eucarióticas. em particular, a invenção inclui composições e métodos para uma expressão melhorada de proteínas de ligação a antígeno, incluindo anticorpos monoespecíficos e biespecíficos em células eucarióticas, particularmente, linhagens de células de hamster chinês (cricetulus griseus), através do emprego de múltiplos loci de potencialização de expressão.
BR112018071283A 2016-04-20 2017-04-20 célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno. BR112018071283A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662325400P 2016-04-20 2016-04-20
PCT/US2017/028555 WO2017184832A1 (en) 2016-04-20 2017-04-20 Compositions and methods for making antibodies based on use of expression-enhancing loci

Publications (1)

Publication Number Publication Date
BR112018071283A2 true BR112018071283A2 (pt) 2019-02-12

Family

ID=58701851

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018071283A BR112018071283A2 (pt) 2016-04-20 2017-04-20 célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno.

Country Status (15)

Country Link
US (2) US11512144B2 (pt)
EP (1) EP3445781A1 (pt)
JP (3) JP7096770B2 (pt)
KR (2) KR20230098361A (pt)
CN (2) CN116515757A (pt)
AR (1) AR109451A1 (pt)
AU (1) AU2017253241A1 (pt)
BR (1) BR112018071283A2 (pt)
CA (1) CA3015389A1 (pt)
EA (1) EA201892010A1 (pt)
IL (1) IL262266A (pt)
MX (1) MX2018012868A (pt)
SG (2) SG10202010155YA (pt)
TW (1) TWI827531B (pt)
WO (1) WO2017184832A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018012868A (es) * 2016-04-20 2019-03-11 Regeneron Pharma Composiciones y metodos para generar anticuerpos basado en el uso de loci potenciadores de expresion.
BR112020012591A2 (pt) * 2017-12-22 2020-11-24 Genentech, Inc. células hospedeiras de integração direcionada (ti), células hospedeiras ti, métodos para preparar uma célula hospedeira ti, métodos para expressar um polipeptídeo de interesse e vetores
AU2019403279A1 (en) * 2018-12-21 2021-07-01 Genentech, Inc. Targeted integration of nucleic acids
KR102655024B1 (ko) * 2019-04-02 2024-04-04 추가이 세이야쿠 가부시키가이샤 표적 특이적인 외래 유전자의 도입 방법
CA3141233A1 (en) 2019-06-26 2020-12-30 Shahram Misaghi Randomized configuration targeted integration of nucleic acids
TW202323529A (zh) 2021-10-18 2023-06-16 美商再生元醫藥公司 包括腺病毒相關病毒聚核苷酸的真核細胞
CA3235566A1 (en) 2021-10-18 2023-04-27 Michael Goren Mammalian cells comprising integrated cas9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sites
TW202330926A (zh) 2021-10-18 2023-08-01 美商再生元醫藥公司 聚核苷酸之受控制轉錄
WO2023122246A1 (en) * 2021-12-22 2023-06-29 Genentech, Inc. Multi-vector recombinase mediated cassette exchange
WO2023238949A1 (ja) * 2022-06-10 2023-12-14 富士フイルム株式会社 細胞の作出方法、ヘテロ多量体タンパク質の製造方法、バイスペシフィック抗体の製造方法、ベクターセット、哺乳動物細胞、ｃｈｏ細胞、及び細胞プールの作出方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6800457B2 (en) 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6406863B1 (en) 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
JP4817657B2 (ja) 2002-05-29 2011-11-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 誘導性の真核生物発現システム
WO2004046340A2 (en) 2002-11-14 2004-06-03 Genentech, Inc. Intron fusion construct and method of using for selecting high-expressing production cell lines
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
AR060070A1 (es) 2006-03-24 2008-05-21 Merck Patent Gmbh Dominios proteicos heterodimericos obtenidos por ingenieria
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
WO2008079943A2 (en) 2006-12-21 2008-07-03 Smithkline Beecham Corporation Novel methods
WO2008089396A1 (en) 2007-01-19 2008-07-24 Invitrogen Corporation Compositions and methods for genetic manipulation and monitoring of cell lines
CN104497143B (zh) 2007-03-29 2020-08-25 健玛保 双特异性抗体及其制造方法
EP2150617B1 (en) 2007-06-04 2014-10-22 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
PL2235064T3 (pl) 2008-01-07 2016-06-30 Amgen Inc Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
KR101641526B1 (ko) * 2009-06-02 2016-07-21 리제너론 파마슈티칼스 인코포레이티드 푸코실화-결핍 세포
CN103833855A (zh) 2009-06-26 2014-06-04 瑞泽恩制药公司 容易地分离的具有天然免疫球蛋白形式的双特异性抗体
SG179196A1 (en) 2009-09-16 2012-04-27 Genentech Inc Coiled coil and/or tether containing protein complexes and uses thereof
JP2013505013A (ja) 2009-09-18 2013-02-14 セレクシス エス．エー． 強化導入遺伝子発現およびプロセッシングの産物および方法
WO2011131746A2 (en) 2010-04-20 2011-10-27 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
CA2808482C (en) 2010-08-16 2021-10-26 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
EP2711428A1 (en) * 2012-09-21 2014-03-26 Lonza Biologics plc. Site-specific integration
WO2014022540A1 (en) * 2012-08-02 2014-02-06 Regeneron Pharmaceuticals, Inc. Multivalent antigen-binding proteins
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TW202206465A (zh) 2012-11-14 2022-02-16 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
EA037255B1 (ru) 2014-10-23 2021-02-26 Регенерон Фармасьютикалз, Инк. Новые сайты интеграции cho и их применения
CA2999385A1 (en) 2015-09-23 2017-03-30 Regeneron Pharmaceuticals, Inc. Optimized anti-cd3 bispecific antibodies and uses thereof
MX2018012868A (es) * 2016-04-20 2019-03-11 Regeneron Pharma Composiciones y metodos para generar anticuerpos basado en el uso de loci potenciadores de expresion.

Also Published As

Publication number Publication date
CN109195986A (zh) 2019-01-11
US11512144B2 (en) 2022-11-29
CA3015389A1 (en) 2017-10-26
AU2017253241A1 (en) 2018-09-20
JP7096770B2 (ja) 2022-07-06
JP2024023449A (ja) 2024-02-21
KR102547738B1 (ko) 2023-06-26
JP2021164479A (ja) 2021-10-14
TWI827531B (zh) 2024-01-01
US20190233544A1 (en) 2019-08-01
KR20180134893A (ko) 2018-12-19
CN109195986B (zh) 2023-01-03
EA201892010A1 (ru) 2019-03-29
EP3445781A1 (en) 2019-02-27
US20230130799A1 (en) 2023-04-27
SG11201807885PA (en) 2018-10-30
MX2018012868A (es) 2019-03-11
TW201803986A (zh) 2018-02-01
CN116515757A (zh) 2023-08-01
AR109451A1 (es) 2018-12-12
SG10202010155YA (en) 2020-11-27
IL262266A (en) 2018-11-29
WO2017184832A1 (en) 2017-10-26
JP2019515666A (ja) 2019-06-13
KR20230098361A (ko) 2023-07-03

Similar Documents

Publication Publication Date Title
BR112018071283A2 (pt) célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno.
BR112018071285A2 (pt) célula, conjunto de vetores, vetor, sistema, e, método
BR112019007288A2 (pt) proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente
MX2021011697A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123.
EA202090931A3 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
PH12016501212A1 (en) Human anti-il-33 neutralizing monoclonal antibody
MX2020010235A (es) Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos.
CL2019000119A1 (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123.
BR112012026766A2 (pt) métodos in vitro para gerar uma proteína heterodimérica, para a seleção de um anticorpo biespecífico e para inibir o crescimento, vetor de expressão, célula hospedeira, proteína heterodimérica, composição farmacêutica.
BR112018010385A2 (pt) anticorpo, receptor de antígeno quimérico, ácido nucleico, célula recombinante, processo para produção de um anticorpo ou um receptor de antígeno quimérico, composição, e, método para detecção de uma célula que expressa cll-1, para diagnóstico de uma doença, para inibição de divisão da célula e para tratamento de um câncer.
MX2018004531A (es) Proteinas de union a antigeno que activan el receptor de leptina.
UY36731A (es) Proteinas de unión contra vegf, pdgf, y/o sus receptores
BR112012018914A2 (pt) "anticorpo humanizado, proteína de ligação de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, proteína de ligação de anticorpo ou de antígeno, métodos para a produção de uma proteína de ligação de antígeno e para tratar um sujeito afetado por uma doença autoimune ou inflamatória, e, composição farmacêutica."
MX2016010791A (es) Inmunoterapia con multiples objetivos dirigida por biomarcadores.
AR115963A1 (es) Anticuerpos anti-il1rap y métodos de uso de estos
EA201892588A1 (ru) Прямой отбор клеток, экспрессирующих высокие уровни гетеромерных белков, с использованием глутаминсинтетазных векторов внутригенной комплементации
EA201791918A1 (ru) Модификация белков клеток-хозяев
EA201691548A1 (ru) Экспрессирующие конструкции и способы для отбора клеток-хозяев, экспрессирующих полипептиды
NZ737423A (en) Method for generating antibodies against t cell receptor
EA201691691A1 (ru) Белки слияния tatk-cdkl5, их композиции, составы и применение
CO2021007882A2 (es) Anticuerpos anti il-36 y procedimientos de uso de estos
BR112021011529A2 (pt) Método para produção de um anticorpo heterodimérico, e, anticorpo biespecífico isolado
AR115992A2 (es) Proteínas de unión a antígeno que activan el receptor de leptina
AR103810A1 (es) Modificación de proteína de célula hospedante
AR111396A1 (es) Moléculas de unión antígeno biespecíficas capaces de unir específicamente a cd40 y a la proteína de activación de fibroblasto (fap)

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]